Meeting
2011 ASCO Annual Meeting
A phase II study of pemetrexed combined with cisplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma.
Authors
A. W. M. Lee
Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
A. W. M. Lee , T. K. Yau , T. C. Shum , W. T. Ng , L. L. Chan , R. M. Yeung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5538)
Abstract #
5538
Poster Bd #
12A
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
First Author: Cong Xue
Poster
2011 ASCO Annual Meeting
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
First Author: J. Guigay
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2023 ASCO Annual Meeting
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).
First Author: Christophe Le Tourneau